VistaGen Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $10.9M
- Price
- $0.244
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.24%
- Volume
- 990.8K
About
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Quick stats
Shares outstanding44.4M
Computed float43.0M
Float / shares97.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001411685
Websitehttps://www.vistagen.com
AI Summary
AI-generated1/36
minormixedearnings
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Vistagen reported fiscal Q1 revenue of $1.48 million, driven by a non-recurring $1.2 million payment from Fuji Pharma, while net loss narrowed to $13.0 million compared to the prior year.
The company provided a clinical update reiterating that fasedienol missed its primary endpoint in the PALISADE-4 trial, though nominally significant efficacy was observed in a very severe social anxiety subpopulation. Management plans to meet with the FDA this quarter to discuss a potential Phase 3 path forward.
Strategic updates include the appointment of a new Chief Medical Officer and a Board member with neuroscience experience. Cash reserves of $31.7 million are expected to fund operations into 2027 but not extend beyond one year.
Red flags
- Cash runway not expected to be sufficient for more than one year from now
- Revenue primarily attributable to a non-recurring milestone payment
- Fasedienol failed to achieve primary endpoint in PALISADE-4 Phase 3 study